Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling

Figure 9

Abrine inhibits liver tumor growth through regulating KAT5/PD-L1 axis. (a, b) HepG2 and Huh7 cells were treated with abrine with or without overexpression of KAT5 or PD-L1. The cell viability (a) and proliferation (b) were measured by CCK-8 and flow cytometry, respectively. (c–e) SCID/nude mice were subcutaneously seeded with HepG2 cells, then treated with PD-L1 antibody and abrine. The tumor size (a) and weight (b) were measured. Level of KI-67 was assessed by IHC staining.

(a)

(b)

(c)

(d)

(e)